ORAL 9NITROCAMPTOTHECIN IN PATIENTS WITH ADVANCED MULLERIAN CANCER

9-硝基喜树碱(9NC)是一种水不溶衍生物。 喜树碱。我的一期研究表明，这种药物在 患有难治性肿瘤的患者，包括卵巢癌。这个 假设9NC对慢性粒细胞白血病患者具有抗肿瘤活性。 以铂为基础的治疗无效的卵巢癌。在此阶段II中 试验中，这种药物将每周口服4天。一个 将进行血浆、全血、尿液和肿瘤的药代动力学研究 对这些患者的细胞进行72小时的结直肠癌。 这项研究已经扩大到包括胰腺癌患者。 并患有骨髓增生异常疾病。将再有四名患者进入 这项研究。

9-nitro-camptothecin (9NC) is a water insoluble derivative of camptothecin. A phase I study has shown that this drug has activity in patients with refractory tumors, including ovarian carcinoma. The hypothesis is that 9NC will have antitumor activity in patients with ovarian carcinoma refractory to platinum-based therapy. In this phase II trial, the drug will be administered orally for 4 days a week. A pharmacokinetic study will be done on plasma, whole blood, urine and tumor cells of these patients for 72 hours on the CRC. The study has been expanded to include patients with pancreatic carcinoma and with myelodysplastic disease. Four more patients will be entered in this study.